There have been worse times for contract biopharmaceutical manufacturers. Studies, surveys and market analyses all come to the same conclusion: the market for therapeutic proteins is continuing to grow in double figures. Current estimates of the total market value are in the range of 60 to 70 billion US dollars, and the market is estimated to grow by 13 per cent p.a. up until 2010. Biopharmaceutical contract manufacturers have established themselves on the market and market observers estimate that the number of biopharmaceutical medicines will grow from 100 (2005) to approx. 150 (2010). A glance into the development pipeline shows that approx. 500 proteins and 150 peptides are in different stages of development with monoclonal antibodies, insulin, interferon beta, G-VSF and coagulation factors being among those drugs with the highest sales. The biosimilar market is regarded as an important future market worth billions of dollars.
Sources:Michael E Kamarck, Building biomanufacturing capacity – the chapter and verse, in: Nature Biotechnology, 25/5, May 2006, S. 503-505Thomas C. Ransohoff, The Rise of Biopharmaceutical Contract Manufacturing, in: BioPharm International 10/2007, S. 165174Jaynant Lakshmikanthan, Outsourcing: Biologics Manufacturing: The CMO Advantage, in: BioPharm International, 1.2.2007Wieland Wolf, Rentscher Holding GmbH & Co. KG, oral communication;German Association of Research-Based Pharmaceutical Companies (VfA)Stephanie Finnegan; Karl Pinto: Offshoring: The Globalization of Outsourced Bioprocessing, in: BioProcess International 4(8), S. 56-62, September 2006William Kerns: Outsourcing: What is the Path Forward? in BioPharm International, 2. April 2007Susan Cameron: Successful Steps for Outsourcing the Manufacture of Clinical Trials Material, in BioPharm International 2. April 2007.William Downey: Biopharmaceutical Contractor Selection, in: Contract Pharma, April 2007.Boehringer Ingelheim, Biotech-Press Conference, Biberach, 9th April 2008.